Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic Hepatitis B

Gut and Liver

Volumn 6, Issue 4, 2012, Pages 486-492

  Choung, Bum Su ^a   Kim, In Hee ^a   Jeon, Byung Jun ^a   Lee, Seok ^a   Kim, Seong Hun ^a   Kim, Sang Wook ^a   Lee, Seung Ok ^a   Lee, Soo Teik ^a   Kim, Dae Ghon ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

2' Fluoro 5 methylarabinosyluracil; Chronic hepatitis B; Muscular diseases; Viral breakthrough

Indexed keywords

ALANINE AMINOTRANSFERASE; CLEVUDINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; SEROCONVERSION; SERODIAGNOSIS; SIDE EFFECT; SOUTH KOREA; WEIGHT REDUCTION;

EID: 84868144671     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.4.486     Document Type: Article

References (19)

1. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L- arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40:380-386.
2. Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998;42:833-839.
3. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178.
4. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048.
5. Kim MH, Kim KA, Lee JS, et al. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009;15:331-337.
6. Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol 2010;16:315-320.
7. Kim IH, Lee S, Kim SH, et al. Treatment outcomes of clevudine versus lamivudine at week 48 in naive patients with HBeAg positive chronic hepatitis B. J Korean Med Sci 2010;25:738-745.
8. Yang HW, Lee BS, Lee TH, et al. Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B. Korean J Intern Med 2010;25:372-376.
9. Shin SR, Yoo BC, Choi MS, et al. A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naive patients with chronic hepatitis B. Hepatol Int 2011;5:664-670.
10. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-2086.
11. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829-834.
12. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261-266.
13. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
14. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
15. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-1703.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
18. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341.
19. Kwon SY, Park YK, Ahn SH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010;84:4494-4503.